Download PDF
Nuklearmedizin 2009; 48(03): N17-N18
DOI: 10.1055/s-0037-1621106
Case report
Schattauer GmbH

Imaging of somatostatin receptor subtype 2 in advanced hepatocellular carcinoma by 68Ga-DOTATOC PET

M. Freesmeyer
1   Departments of Nuclear Medicine, University Hospital Jena, Germany
,
St. Schulz
2   Departments of Pharmakology and Toxcology, University Hospital Jena, Germany
,
T. Knösel
3   Departments of Pathology, University Hospital Jena, Germany
,
U. Settmacher
4   Departments of General, Visceral and Vascular Surgery, University Hospital Jena, Germany
› Author Affiliations
Further Information

Publication History

Received: 22 July 2008

accepted in revised form: 08 October 2008

Publication Date:
20 January 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Becker G, Allgaier HP, Olschewski M. et al. HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45: 9-15.
    PubMedGoogle Scholar
  • 2 Bläker M, Schmitz M, Gocht A. et al. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. Journal of Hepatology 2004; 41: 112-118.
    CrossrefPubMedGoogle Scholar
  • 3 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K. et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007; 13: 3164-3170.
    CrossrefPubMedGoogle Scholar
  • 4 Fischer T, Doll C, Jacobs S. et al. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal anti-sstr2 antibody UMB-1. J Clin Endo Metab 2008; 93: 4519-4524.
    CrossrefPubMedGoogle Scholar
  • 5 Liu HL, Huo L, Wang L. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 2004; 25: 1380-1386.
    PubMedGoogle Scholar
  • 6 Raderer M, Hejna MH, Muller C. et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16: 1197-1201.
    PubMedGoogle Scholar
  • 7 Rahmi G, Malka D, Tomasic G. et al. Complete, longstanding regression of hepatocellular carcinoma after somatostatin analogue treatment. J Clin Oncol 2007; 25: e15-e16.
    CrossrefPubMedGoogle Scholar
  • 8 Reynaert H, Rombouts K, Vandermonde A. et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004; 53: 1180-1189.
    CrossrefPubMedGoogle Scholar
  • 9 Siveke JT, Herberhold C, Folwaczny C. Complete regression of advanced HCC with long acting octreotide. Gut 2003; 52: 1531.
    CrossrefPubMedGoogle Scholar
  • 10 Verhoef C, van Dekken H, Hofland LJ. et al. Somatostatin Receptor in Human Hepatocellular Carcinomas: Biological, Patient and Tumor Characteristics. Dig Surg 2008; 25: 21-26.
    CrossrefPubMedGoogle Scholar
  • 11 Verset G, Verslype C, Reynaert H. et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocel- lular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007; 97: 582-588.
    CrossrefPubMedGoogle Scholar
  • 12 Yong Li, Jian-Ming Si, Jun Zhang. et al. Somatostatin receptor subtype 2-mediated scintigraphy and localization using 99mTc-HYNIC-Tyr3-octreotide in human hepatocellular carcinoma-bearing nude mice. World J Gastroenterol 2005; 11: 3953-3957.
    CrossrefPubMedGoogle Scholar